Scholefield J H, Moss S, Sufi F, Mangham C M, Hardcastle J D
Division of GI Surgery, University Hospital, Nottingham NG7 2UH, UK.
Gut. 2002 Jun;50(6):840-4. doi: 10.1136/gut.50.6.840.
Three large randomised trials have shown that screening for colorectal cancer using faecal occult blood (FOB) tests can reduce the mortality from this disease. Two national pilot studies have recently been launched in the UK to investigate the feasibility of population screening for colorectal cancer in the National Health Service. The largest of the randomised trials was conducted in Nottingham and randomised 152 850 individuals between the ages of 45 and 74 years to receive biennial Haemoccult (FOB) test kit (intervention group) or to a control group.
We have compared the mortality in the intervention group compared with the control group.
The 152 850 randomised individuals were followed up through local health records and central flagging (Office for National Statistics) over a median follow up period of 11 years.
At a median follow up of 11 years there was a 13% reduction in colorectal cancer mortality (95% confidence interval 3-22%) in the intervention group despite an uptake at first invitation of only approximately 50%. The mortality reduction for those accepting screening was 27%. The reduction in mortality was independent of sex and site of tumour. There was no significant difference in mortality from causes other than colorectal cancer between the intervention and control groups.
Although the reduction in colorectal cancer mortality was sustained, further follow up of this population is required to determine whether a significant reduction in the incidence of colorectal cancer will be achieved.
三项大型随机试验表明,使用粪便潜血(FOB)检测筛查结直肠癌可降低该病的死亡率。英国最近开展了两项全国性试点研究,以调查在国民医疗服务体系中对结直肠癌进行人群筛查的可行性。规模最大的随机试验在诺丁汉进行,将152850名年龄在45至74岁之间的个体随机分为两组,一组每两年接受一次隐血(FOB)检测试剂盒(干预组),另一组为对照组。
我们比较了干预组与对照组的死亡率。
通过当地健康记录和中央标记(国家统计局)对152850名随机分组的个体进行了为期11年的中位随访。
在11年的中位随访期内,干预组的结直肠癌死亡率降低了13%(95%置信区间为3%-22%),尽管首次邀请时的接受率仅约为50%。接受筛查者的死亡率降低了27%。死亡率的降低与性别和肿瘤部位无关。干预组和对照组在结直肠癌以外原因导致的死亡率方面没有显著差异。
尽管结直肠癌死亡率的降低是持续的,但仍需要对该人群进行进一步随访,以确定结直肠癌发病率是否会显著降低。